Oxford BioDynamics Plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Richard Compton
- Full Time Employees
- 37
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 3140 Rowan Place Oxford OX United Kingdom OX4 2WB
- IPO Date
- Dec 6, 2016
- Website
- oxfordbiodynamics.com
- Similar Companies
- Business
- Oxford BioDynamics Plc is a United Kingdom-based biotechnology company that advances personalized healthcare through the development and commercialization of precision medicine tests based on its proprietary EpiSwitch platform, which enables 3D genomics for clinical applications in diagnostics and biomarker research. The company offers a portfolio of clinical smart tests including EpiSwitch CiRT, a blood-based Checkpoint Inhibitor Response Test that predicts patient responses to immunotherapy for cancer treatment; EpiSwitch PSE, a prognostic screening test for prostate cancer risk; EpiSwitch Explorer, a microarray kit for high-throughput 3D genome profiling and biomarker discovery; and Specimen Submission Kits for sample collection, partnering with CLIA-certified labs to deliver these to physicians worldwide. Founded in 2007 and headquartered at 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, United Kingdom, it maintains operations including offices and labs in Oxford, UK; Gaithersburg and Frederick, Maryland, USA; and an ISO-certified laboratory in Penang, Malaysia, targeting healthcare providers, pharmaceutical companies, and patients with life-changing diseases such as cancer. Recent developments include a commercial agreement in January 2025 with Romania's Regina Maria Private Health Network to expand EpiSwitch PSE distribution; a strategic fundraising of £7 million in November 2025 via placing and subscriptions to support commercialization and partnerships; initiation of cost-saving measures and a strategic review in October 2024; a new partnership with Google Cloud advancing platform capabilities; and ongoing discussions for licensing and collaborations with large pharmaceutical, biotech, and diagnostic firms to monetize its assets including over 40 prior partnerships with entities like Pfizer, Roche, and Genentech.
Company News
Oxford BioDynamics shares soar 33% after unveiling breakthrough blood test for Chronic Fatigue Syndrome
Oxford BioDynamics unveils blood test for Chronic Fatigue Syndrome with 96% accuracy
Oxford BioDynamics shares climb blood test findings
Oxford BioDynamics partners with Google Cloud - ICYMI
Oxford BioDynamics soars on new Google collab
Oxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology
Oxford BioDynamics shares jump on UK lab accreditation for flagship cancer test
Oxford BioDynamics slumps on warning of need for new funding
Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy
Oxford Biodynamics tumbles as results knock froth off recent gains